Xenon Pharmaceuticals Share Price Today

Xenon Pharmaceuticals holds $1.2 billion cash to fund operations into 2029

Cash reserves stand at $1.2 billion, funding operations into 2029. NDA submitted for AZK in focal seizures with 42.7% placebo-adjusted efficacy in Phase 3. Top-line data for EXNOVA-2 study in MDD expected in December 2026. Two pain candidates advancing to Phase 2 proof-of-concept studies after positive Phase 1 data.

Wolf Popper probes Xenon Pharmaceuticals after 30.7% stock drop

Xenon Pharmaceuticals stock fell 30.7% to $39.75 following a clinical trial pause announcement. Wolf Popper LLP is investigating potential securities claims for shareholders who suffered losses. The pause affects enrollment in Phase 3 trials for major depressive disorder and bipolar depression. Lead drug candidate azetukalner faced scrutiny due to neuropsychiatric adverse events in studies.

Xenon Pharmaceuticals grants 17,850 options and 10,500 RSUs to new hires

Xenon Pharmaceuticals granted 17,850 share options and 10,500 RSUs to eight new non-officer employees. Share options have an exercise price of $38.93, matching the closing price on October 1, 2026. Options vest over four years with a one-year cliff, while RSUs vest 25% annually for four years. Grants were approved by the Compensation Committee as inducements under Nasdaq Listing Rule 5635(c)(4).

Xenon Pharmaceuticals shares drop 30.7% after pausing Phase 3 trials

Xenon Pharmaceuticals shares fell 30.7% after pausing Phase 3 trial enrollment. Safety review revealed neuropsychiatric adverse events not seen in Phase 2. Needham removed all MDD and bipolar sales projections; Deutsche Bank downgraded to Hold. Topline data for X-NOVA2 expected in Q1 2027 at ~360 of 450 patients. Levi & Korsinsky LLP investigating potential misleading statements regarding safety.

Xenon Pharmaceuticals to present at TD Cowen neuropsychiatry summit

Xenon Pharmaceuticals to present at TD Cowen Summit on Sept 23. Virtual fireside chat scheduled for 2:00-2:25 pm ET. Lead asset azetukalner in late-stage trials for epilepsy and depression. Early-stage pain programs targeting K_V7 and Na_V1.7 channels.

Xenon shares fall 29% on psychiatry trial pause; analyst calls reaction overblown

Xenon shares fell 29.22% to $40.59 on Friday following a psychiatry trial pause. William Blair analyst called the reaction overblown, citing comparable safety profiles in approved drugs. Company submitted NDA for azetukalner for focal seizures based on Phase 2b/3 data. Enrollment pause does not impact ongoing epilepsy studies or already enrolled psychiatry patients. Topline data for Phase 3 MDD study X-NOVA2 expected in Q1 2027.